Single-cell transcriptional regulation and genetic evolution of neuroendocrine prostate cancer
- PMID: 35789834
- PMCID: PMC9250006
- DOI: 10.1016/j.isci.2022.104576
Single-cell transcriptional regulation and genetic evolution of neuroendocrine prostate cancer
Abstract
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer, with a 10% five-year survival rate. However, little is known about its origin and the mechanisms governing its emergence. Our study characterized ADPC and NEPC in prostate tumors from 7 patients using scRNA-seq. First, we identified two NEPC gene expression signatures representing different phases of trans-differentiation. New marker genes we identified may be used for clinical diagnosis. Second, integrative analyses combining expression and subclonal architecture revealed different paths by which NEPC diverges from the original ADPC, either directly from treatment-naïve tumor cells or from specific intermediate states of treatment-resistance. Third, we inferred a hierarchical transcription factor (TF) network underlying the progression, which involves constitutive regulation by ASCL1, FOXA2, and selective regulation by NKX2-2, POU3F2, and SOX2. Together, these results defined the complex expression profiles and advanced our understanding of the genetic and transcriptomic mechanisms leading to NEPC differentiation.
Keywords: Cancer; Cancer systems biology; Transcriptomics.
© 2022 The Author(s).
Figures







Similar articles
-
Longitudinal single-cell analysis reveals RUNX1T1 as an early driver in treatment-induced neuroendocrine transdifferentiation.bioRxiv [Preprint]. 2025 May 18:2025.05.14.653660. doi: 10.1101/2025.05.14.653660. bioRxiv. 2025. PMID: 40463134 Free PMC article. Preprint.
-
The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.Cancer Discov. 2017 Jan;7(1):54-71. doi: 10.1158/2159-8290.CD-15-1263. Epub 2016 Oct 26. Cancer Discov. 2017. PMID: 27784708
-
SOX2 has dual functions as a regulator in the progression of neuroendocrine prostate cancer.Lab Invest. 2020 Apr;100(4):570-582. doi: 10.1038/s41374-019-0343-5. Epub 2019 Nov 26. Lab Invest. 2020. PMID: 31772313
-
Molecular model for neuroendocrine prostate cancer progression.BJU Int. 2018 Oct;122(4):560-570. doi: 10.1111/bju.14207. Epub 2018 Apr 24. BJU Int. 2018. PMID: 29569310 Review.
-
Clinical and Biological Features of Neuroendocrine Prostate Cancer.Curr Oncol Rep. 2021 Jan 12;23(2):15. doi: 10.1007/s11912-020-01003-9. Curr Oncol Rep. 2021. PMID: 33433737 Free PMC article. Review.
Cited by
-
Application and new findings of scRNA-seq and ST-seq in prostate cancer.Cell Regen. 2024 Oct 29;13(1):23. doi: 10.1186/s13619-024-00206-w. Cell Regen. 2024. PMID: 39470950 Free PMC article. Review.
-
Widespread activation and critical role of EMT and stemness in the neuroendocrine differentiation of prostate cancer (Review).Oncol Rep. 2025 Sep;54(3):109. doi: 10.3892/or.2025.8942. Epub 2025 Jul 11. Oncol Rep. 2025. PMID: 40641143 Free PMC article. Review.
-
Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation.Cancer Metastasis Rev. 2024 Mar;43(1):229-260. doi: 10.1007/s10555-024-10168-9. Epub 2024 Feb 19. Cancer Metastasis Rev. 2024. PMID: 38374496 Review.
-
Complexities of Prostate Cancer.Int J Mol Sci. 2022 Nov 17;23(22):14257. doi: 10.3390/ijms232214257. Int J Mol Sci. 2022. PMID: 36430730 Free PMC article. Review.
-
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer.Res Sq [Preprint]. 2024 Mar 27:rs.3.rs-4095949. doi: 10.21203/rs.3.rs-4095949/v1. Res Sq. 2024. Update in: Oncogene. 2024 Jul;43(30):2325-2337. doi: 10.1038/s41388-024-03081-6. PMID: 38585965 Free PMC article. Updated. Preprint.
References
-
- Aggarwal R., Huang J., Alumkal J.J., Zhang L., Feng F.Y., Thomas G.V., Weinstein A.S., Friedl V., Zhang C., Witte O.N., et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 2018;36:2492–2503. doi: 10.1200/JCO.2017.77.6880. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous